RecruitingPhase 1Phase 2NCT06087458

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration

Sponsor

Perceive Biotherapeutics, Inc.

Enrollment

60 participants

Start Date

Jun 21, 2023

Study Type

INTERVENTIONAL

Conditions

Geographic Atrophy Age-Related Macular Degeneration Non-neovascular AMD

Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Eligibility

Min Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called VOY-101 for people with age-related macular degeneration, geographic atrophy, and other related conditions. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 60 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALVOY-101

VOY-101

Locations(11)

Retina Macula Institute of AZ

Scottsdale, Arizona, United States

The Retina Partners

Encino, California, United States

Retinal Consultants Medical Group

Sacramento, California, United States

Retina Consultants San Diego

San Diego, California, United States

Star Retina

Burleson, Texas, United States

Retina Center of Texas

Southlake, Texas, United States

University of Utah John A. Moran Eye Center

Salt Lake City, Utah, United States

Sydney Retina Clinic and Day Surgery

Sydney, New South Wales, Australia

Cerulea Clinical Trials

East Melbourne, Victoria, Australia

Rambam Medical Center

Haifa, Israel

Tel-Aviv Sourasky Medical Center, Ophthalmology Division

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06087458

Related Trials

Effects of Goji vs. Fiber on Macular Degeneration

NCT062371271 location

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT0562611417 locations

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT071601795 locations

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT0744022587 locations

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT0749656756 locations